首页 | 本学科首页   官方微博 | 高级检索  
     

缬沙坦与雷公藤多苷及川芎嗪联合治疗糖尿病肾病蛋白尿的效果研究
引用本文:查华英,史耀勋. 缬沙坦与雷公藤多苷及川芎嗪联合治疗糖尿病肾病蛋白尿的效果研究[J]. 中国现代医生, 2014, 0(7): 62-64
作者姓名:查华英  史耀勋
作者单位:[1]浙江省德清县中医医院内科病区,浙江德清313200 [2]吉林省中医药科学院肾病科,吉林长春130021
基金项目:吉林省中医药管理局中医药科技项目(2012-SC018)
摘    要:目的探讨采用缬沙坦联合雷公藤多苷、川芎嗪对糖尿病肾病蛋白尿进行治疗的临床效果。方法对2011年3月~2013年8月到我院就诊的93例2型糖尿病肾病患者的临床资料进行回顾性分析,将入选患者按照治疗方法不同分成两组,其中对照组患者46例,采用缬沙坦胶囊治疗,观察组患者47例,采用缬沙坦胶囊、雷公藤多苷及川芎嗪治疗,比较两组患者的治疗总有效率及治疗前后UAER、24 h尿蛋白定量、SCr、BUN、HbA1c水平。结果观察组患者的治疗总有效率为97.87%,明显高于对照组的89.13%,差异有统计学意义(P<0.05)。治疗后观察组及对照组患者UAER、24 h尿蛋白定量、SCr、BUN及HbA1c均明显降低,差异有统计学意义(P<0.05)。观察组治疗后UAER及24 h尿蛋白定量明显低于对照组,IgG、IgA、C3、C4均高于对照组,差异均有统计学意义(P<0.05)。结论糖尿病肾病患者在常规治疗的基础上采用缬沙坦联合雷公藤多苷、川芎嗪治疗能降低蛋白尿水平,具有较高的安全性,可以在临床推广应用。

关 键 词:糖尿病肾病  蛋白尿  缬沙坦  雷公藤多苷  川芎嗪

Clinical observation on the diabetic nephropathy treated with valsartan TWP,ligustrazine
ZHA Huaying,SHI Yaoxun. Clinical observation on the diabetic nephropathy treated with valsartan TWP,ligustrazine[J]. , 2014, 0(7): 62-64
Authors:ZHA Huaying  SHI Yaoxun
Affiliation:1.Medicine Ward, Zhejiang Province Deqing County Chinese Medicine Hospital, Deqing 313200, China; 2.Nephrology Department, Jilin Province Academy of Traditional Chinese Medicine, Changchun 130021, China
Abstract:Objective To explore the effect of the diabetic Nephropathy treated with valsartan TWP, ligustrazine. Methods Retrospectively analyzed the clinical data of 93 cases of type 2 diabetic nephropathy patients who were collected from March 2011 to August 2013 in our hospital, the patients were divided into two groups according to the different treatment methods, the control group included 46 patients, treated with valsartan capsules, the observation group included 47 patients, treated with valsartan capsules, TWP and ligustrazine treatment. The total efficiency, UAER, 24 h urinary protein, SCr , BUN, HbAlc of two groups before and after the treatment were compared. Results The total effective rate of observation group was 97.87%, was significantly higher than the control group 89.13%, with significant difference (P〈0.05). UAER, 24 h urinary protein, SCr, BUN and HbAlc of the observation group and the control group after treatment were significant lower than before treatment, with significant differenee (P 〈0.05). UAER and 24 h urinary protein excretion of the observation group after treatment were significantly lower than the control group, while IgG,IgA,C3,C4 of the observation group after treatment were higher than the control group, had significant difference(P〈 0.05). Conclusion Diabetic nephropathy patients in the conventional therapy based on the use of valsartan TWP, ligustrazine treatment can reduce the level of proteinuria, with high security, can be widely used in the clinical.
Keywords:Diabetic nephropathy  Albuminuria  Valsartan  TWP  Ligustrazine
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号